Research in Brief

Abstract

The multivalent nanobody TNF inhibitor ozoralizumab could be a safe and effective treatment for rheumatoid arthritis, according to the results of a phase 2/3 randomised trial by Tsutomu Takeuchi and colleagues. 381 patients were randomly assigned to receive 30 mg ozoralizumab (n=152), 80 mg ozoralizumab (n=154), or placebo (n=75) subcutaneously every 4 weeks concomitant with methotrexate (6–16 mg/week) for 24 weeks. At week 16, 121 (79·6%) of patients on 30 mg ozoralizumab and 116 (75·3%) on 80 mg ozoralizumab had a 20% improvement in the American College of Rheumatology criteria (ACR20 response; the primary outcome) versus 28 (37·3%) on placebo (p<0·0001 for both doses).